Clinical-stage biotechnology company focused on research and development of therapeutic candidates; currently pre-revenue and primarily funded through equity financings.

# Unnamed Company

Below are the section headings you provided from the company filing:

- Part I
  - Item 1. Business
  - Item 1A. Risk Factors
  - Item 1B. Unresolved Staff Comments
  - Item 1C. Cybersecurity
- Item 2. Properties
- Item 3. Legal Proceedings
- Item 4. Mine Safety Disclosures

What I can deliver once you provide the actual content:
- A clear, plain-language summary of the company’s business and operations, including core business description and principal products/services
- Markets served and geographic footprint
- Key competitive advantages or differentiators
- Number of customers (if stated)
- Number of employees (if stated)
- Revenue (latest fiscal year) and net income (if stated)
- A concise summary of major risk factors from Item 1A
- Cybersecurity posture highlights from Item 1C
- Significant properties or facilities from Item 2
- Status or highlights of legal proceedings from Item 3
- Mine safety disclosures if applicable (Item 4)

How to proceed:
- Paste the full text from Item 1. Business, Item 1A. Risk Factors, Item 1B. Unresolved Staff Comments, Item 1C. Cybersecurity, Item 2. Properties, Item 3. Legal Proceedings, and Item 4. Mine Safety Disclosures, or upload the document.
- I will then generate a concise, detailed markdown summary that includes exact numbers for customers, employees, revenue, and income where they appear in the provided content.

Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for neurodegenerative diseases such as Alzheimer's and Parkinson's through its lead product candidate, buntanetap.


# Company Overview: Annovis Bio, Inc.

## Business Focus
Annovis Bio, Inc. is a late-stage clinical drug platform company focused on developing therapeutics for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD). Their lead product candidate, **buntanetap**, is designed to inhibit neurotoxic proteins, including APP/Aβ, tau, and α-Synuclein, which are implicated in neurodegeneration. Buntanetap is an orally administered small molecule that shows potential for addressing cognitive decline in AD and motor dysfunction in PD.

## Key Product: Buntanetap
- **Mechanism of Action:** Buntanetap is designed as a translational inhibitor of neurotoxic aggregating proteins. It specifically targets the over-translation of these proteins, thereby reducing their levels and reversing the neurotoxic cascade leading to nerve cell death.
- **Clinical Development:** Annovis has conducted multiple clinical studies including:
  - **Phase 1/2 Studies:** Conducted in 2021 involving early AD (14 patients) and early PD (54 patients).
  - **Phase 3 PD Study:** Initiated in August 2022, completed in December 2023, involving 450 early PD patients across 53 U.S. and 49 EU sites. Topline data released on July 2, 2024, indicated significant improvements in both cognition and motor function.
  - **Phase 2/3 AD Study:** Initiated in February 2023 for 750 mild to moderate AD patients, combining a 6-month symptomatic efficacy trial with a 12-month extension to demonstrate disease-modifying effects.

## Pipeline Products
1. **Buntanetap:** Targeting chronic neurodegeneration (AD, PD).
2. **ANVS405:** An intravenous formulation for acute neurodegeneration.
3. **ANVS301:** Developed for cognitive enhancement in later stages of AD.

## Financial Overview
- **Customers:** The company primarily operates in the biopharmaceutical space, addressing the growing patient demographics suffering from neurodegenerative diseases. While specific customer numbers are not disclosed, the potential market includes millions of AD and PD patients globally.
- **Employees:** Specific headcount is not given, but the leadership team consists of experienced professionals with extensive industry knowledge.
- **Revenue:** Not detailed in the provided text; Annovis is likely still in the clinical development phase, which typically precedes revenue generation.
- **Income:** Specific income figures are not disclosed; the focus remains on clinical studies and development of its drug candidates.

## Leadership Team
- **Maria L. Maccecchini:** Founder, President, and CEO with a background in biochemistry and extensive industry experience.
- **Cheng Fang:** Senior VP, R&D, specializing in neurodegenerative diseases.
- **Eve Damiano:** Senior VP, Regulatory, with over 35 years in biotechnology focusing on regulatory strategies.
- **Melissa Gaines:** Senior VP, Clinical Operations, with significant experience in clinical research.
- **Mike Christie:** VP, Process Chemistry, with over 40 years in the pharmaceutical industry.
- **Andrew Walsh:** VP, Finance, with diverse finance experience in public and private companies.

## Future Development Plans
- **AD and PD Trials:** 
  - Phase 3 AD study is expected to read out 6-month symptomatic efficacy data in the second half of 2026 and 18-month disease-modifying data in the second half of 2027.
  - Plans to propose a pivotal Phase 3 trial for PD to the FDA in 2025.

## Summary
Annovis Bio, Inc. is working to potentially revolutionize treatment for neurodegenerative diseases through innovative therapies like buntanetap, targeting the root causes of these debilitating conditions. While still in the clinical trial phase, the company shows promise for addressing significant unmet medical needs in the aging population.



Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases, particularly Alzheimer's and Parkinson's diseases.

# Annovis Bio, Inc. Overview

## Company Profile
- **Name:** Annovis Bio, Inc.
- **Incorporation:** Established in Delaware in May 2008.
- **Headquarters:** 101 Lindenwood Drive, Suite 225, Malvern, PA 19355.

## Business Focus
Annovis Bio is a clinical stage biopharmaceutical company dedicated to developing therapies for neurodegenerative diseases, specifically targeting Alzheimer’s disease (AD) and Parkinson’s disease (PD). 

### Lead Product Candidate
- **Name:** Buntanetap
- **Mechanism of Action:** A small-molecule, orally administered translational inhibitor designed to inhibit the synthesis of neurotoxic proteins (APP/Aβ, tau, phospho-tau, α-Synuclein) that contribute to neurodegeneration by:
  - Lowering neurotoxic protein levels
  - Restoring nerve cell axonal and synaptic activity
- **Clinical Status:** 
  - Completed Phase 1/2 trials in 2021 involving:
    - 14 early AD patients
    - 54 early PD patients
  - Ongoing Phase 3 trial for early PD patients initiated in August 2022.
  - Ongoing Phase 2/3 trial for mild to moderate AD patients initiated in February 2023.

### Pipeline
- **ANVS405:** An intravenous formulation for acute neurodegeneration, including traumatic brain injury (TBI) and stroke.
- **ANVS301:** A product candidate targeting advanced Alzheimer’s disease.

## Operations and Financials
- **Employees:** As of February 29, 2024, the company has 6 full-time employees and utilizes the services of 10 part-time employees or consultants.
- **Revenue:** The company has not yet generated revenue from commercializing any product. It has incurred net losses, reporting $56.2 million for the year ended December 31, 2023 and $25.3 million for the previous year.
- **Income:** As of December 31, 2023, Annovis had an accumulated deficit of approximately $110.3 million.

## Clinical Trials and Market Focus
Annovis believes it may be the only company seeking to develop a drug that targets multiple neurotoxic proteins involved in Alzheimer’s and Parkinson’s diseases. If successful, this could provide a significant competitive advantage in a market with high unmet medical needs.

- **Potential Market Size:**
  - Alzheimer's disease currently affects approximately 6 million people in the U.S., with projections suggesting the number could exceed 100 million worldwide by 2050.
  - Parkinson's disease affects about 10 million people globally.

## Vision and Goals
- **Future Plans:** By the end of 2026, the company aims to complete the pivotal studies necessary to file two new drug applications (NDAs) with the FDA.
- **Market Strategy:** Plans to commercialize its products through collaborations with pharmaceutical companies, targeting neurologists and geriatric specialists. 

## Unique Selling Proposition
Annovis positions itself as a pioneer in targeting multiple neurotoxic proteins, with the expectation that a successful therapy could provide significant advancements in treatment options for both Alzheimer’s and Parkinson’s disease patients.

---

This overview captures the essence of Annovis Bio, Inc. as it stands in terms of business operations, focus areas, and financial health.

Annovis Bio, Inc.

10-K / March 13, 2026

10-K / March 21, 2025

10-K / March 29, 2024

10-K / March 13, 2026

Unnamed Company